These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30488338)

  • 1. Adherence to Subcutaneous IFN β-1a in Multiple Sclerosis: Final Analysis of the Non-Interventional Study READOUTsmart Using the Dosing Log and Readout Function of RebiSmart
    Rieckmann P; Schwab M; Pöhlau D; Penner IK; Wagner T; Schel E; Bayas A
    Adv Ther; 2019 Jan; 36(1):175-186. PubMed ID: 30488338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
    Zecca C; Disanto G; Mühl S; Gobbi C
    BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
    Piras F; Arnaud L; Henninger E; Keiser M; Seitzinger A; Jack D; Le Masne Q
    Expert Opin Drug Deliv; 2023 Jun; 20(6):863-870. PubMed ID: 37273189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
    Bayas A; Ouallet JC; Kallmann B; Hupperts R; Fulda U; Marhardt K;
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1239-50. PubMed ID: 26098143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart
    Rieckmann P; Ziemssen T; Penner IK; Raji A; Wagner T; Richter J; Zettl UK
    Adv Ther; 2022 Jun; 39(6):2749-2760. PubMed ID: 35428903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
    Devonshire VA; Feinstein A; Moriarty P
    BMC Res Notes; 2016 Mar; 9():148. PubMed ID: 26951043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study.
    Deftereos SN; Koutlas E; Koutsouraki E; Kyritsis A; Papathanassopoulos P; Fakas N; Tsimourtou V; Vlaikidis N; Tavernarakis A; Voumvourakis K; Arvanitis M; Sakellariou D; DeLorenzo F
    BMC Neurol; 2018 Nov; 18(1):186. PubMed ID: 30400884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
    Lugaresi A; De Robertis F; Clerico M; Brescia Morra V; Centonze D; Borghesan S; Maniscalco GT;
    Expert Opin Drug Deliv; 2016 Jul; 13(7):931-5. PubMed ID: 26909646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis.
    Sauri-Suárez S; Quiñones-Aguilar S; Contreras-Marín A; Ramiro-Guerrero EO; Zúñiga-García D; Salinas-Vázquez L; Llamas-López L; León-Jiménez C; García-Martell A; González-Hernández I; Chiquete E; García S
    PLoS One; 2020; 15(4):e0230959. PubMed ID: 32310950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.
    Fernández O; Arroyo R; Martínez-Yélamos S; Marco M; Merino JA; Muñoz D; Merino E; Roque A;
    PLoS One; 2016; 11(8):e0160313. PubMed ID: 27526201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device.
    Willis H; Webster J; Larkin AM; Parkes L
    Patient Prefer Adherence; 2014; 8():843-51. PubMed ID: 24966669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
    Lugaresi A; Florio C; Brescia-Morra V; Cottone S; Bellantonio P; Clerico M; Centonze D; Uccelli A; di Ioia M; De Luca G; Marcellusi A; Paolillo A;
    BMC Neurol; 2012 Mar; 12():7. PubMed ID: 22390218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
    Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
    BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment.
    Pavelek Z; Novotný M; Klímová B; Peterka M; Potužník P; Kövári M; Vališ M
    Curr Med Res Opin; 2021 Apr; 37(4):589-596. PubMed ID: 33538199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational study demonstrating the adherence and ease of use of the injector device, RebiSmart®.
    Vališ M; Šarláková J; Halúsková S; Klímová B; Potužník P; Peterka M; Kuča K; Štourač P; Mareš J; Pavelek Z
    Expert Opin Drug Deliv; 2020 May; 17(5):719-724. PubMed ID: 32315204
    [No Abstract]   [Full Text] [Related]  

  • 18. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
    Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
    BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
    Ernst FR; Barr P; Elmor R; Wong SL
    Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.